StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

Analysts at StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

A number of other equities analysts also recently weighed in on the stock. Barclays boosted their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $56.83.

Catalent Trading Down 0.4 %

Catalent stock opened at $59.55 on Friday. Catalent has a one year low of $31.80 and a one year high of $60.20. The company has a market cap of $10.78 billion, a price-to-earnings ratio of -9.76, a P/E/G ratio of 2.47 and a beta of 1.16. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The firm has a 50-day moving average of $57.63 and a 200-day moving average of $56.71.

Insider Buying and Selling

In other news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares in the company, valued at $2,360,264.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ricky Hopson sold 1,401 shares of the stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,810 shares of company stock worth $858,941. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of institutional investors have recently made changes to their positions in the stock. Lindbrook Capital LLC boosted its holdings in Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the last quarter. GAMMA Investing LLC acquired a new position in Catalent in the fourth quarter valued at $33,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent during the second quarter valued at $42,000. Mather Group LLC. acquired a new stake in Catalent during the 1st quarter worth about $52,000. Finally, Longfellow Investment Management Co. LLC grew its holdings in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.